Epilepsy Project CGO1 progressing through optimization activities in preparation for in-human studies 

In June, CombiGene and Spark Therapeutics held a bi-annual Joint Research Committee meeting in Stockholm, Sweden, to make a detailed plan for the upcoming six months. Significant progress has been made in the gene therapy field since CG01 was first designed, both in terms of manufacturing and in the formulation of  gene therapies. For the epilepsy project CG01, this means that now is the perfect time to take full advantage of this new and important knowledge and optimize some of the components of the project before moving it towards clinical studies.

Using the combined strength of CombiGene and Spark, the two companies are now engaged in optimization of the therapeutic AAV to achieve improved coverage of the brain regions affected by epilepsy.

“The Joint Research Committee meeting in Stockholm was highly productive, and again proved that we have an ideal partner in Spark”, says Karin Agerman, Chief Scientific Officer at CombiGene. “I am really happy about the decision to optimize some of the components of the project. By doing this, we will be in a much more advantageous position once the project enters in-human studies,” Karin concludes.

Share the article: